Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer

Trial Profile

Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Jan 2019

At a glance

  • Drugs ALRN 6924 (Primary) ; Cytarabine
  • Indications Acute myeloid leukaemia; Hepatoblastoma; Precursor cell lymphoblastic leukaemia-lymphoma; Retinoblastoma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Nov 2018 According to an Aileron Therapeutics media release, this trial is being conducted under and agreement between the company and the Dana-Farber/Boston Children's Cancer and Blood Disorders Center.
    • 18 Oct 2018 Planned initiation date (anticipated data of first patient enrolment) changed from 30 Sep 2018 to 30 Nov 2018.
    • 18 Oct 2018 Planned number of patients changed from 6 to 69.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top